Lenalidomide-Br

製品コードS1016 バッチS101601

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₁₃H₁₁BrN₂O₃

分子量

323.14

CAS No.

2093387-36-9

Solubility (25°C)*

体外

DMSO

21 mg/mL (64.98 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.05mg/ml (3.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 21 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.15mg/ml (0.46mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Lenalidomide-Br is a brominated analog of lenalidomide, designed for use as a chemical tool in PROTAC research. It serves as a cereblon (CRBN)-recruiting ligand, enabling targeted protein degradation through the CRL4CRBN E3 ubiquitin ligase complex.

プロトコル(参考用のみ)

参考

https://pubmed.ncbi.nlm.nih.gov/37596276/
https://pubmed.ncbi.nlm.nih.gov/36986673/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma [ Nat Commun, 2022, 13(1):1009]	PubMed: 35197447
NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma [ Cell Death Dis, 2022, 13(3):197]	PubMed: 35236820
SORT1/LAMP2-mediated Extracellular Vesicle Secretion and Cell Adhesion Are Linked to Lenalidomide Resistance in Multiple Myeloma [ Blood Adv, 2022, bloodadvances.2021005772]	PubMed: 34979567
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma [ Nat Commun, 2021, 12(1):5183]	PubMed: 34465776
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation [ Blood Cancer J, 2021, 11(12):194]	PubMed: 34864816
IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK [ Leukemia, 2021, 35(5):1330-1343]	PubMed: 33623139
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma [ Blood Adv, 2021, 5(9):2391-2402]	PubMed: 33950175
IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform [ Cell Death Discov, 2021, 7(1):139]	PubMed: 34117218
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells [ Hemasphere, 2021, 5(7):e602]	PubMed: 34136753
Fractionated Irradiation of Right Thorax Induces Abscopal Damage on Bone Marrow Cells via TNF-α and SAA [ Int J Mol Sci, 2021, 22(18)9964]	PubMed: 34576128

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。